KYMERA

Kymera Therapeutics

Kymera is working to reinvent the treatment of human disease through the development of innovative, highly differentiated medicines that address critical health problems and dramatically improve patient's lives. We are committed to advancing novel technologies, such as Targeted Protein Degradation (TPD), to tackle previously undrugged disease causing proteins that have escaped existing modalities and challenging conventional treatment paradigms to deliver a new generation of medicines in a disease agnostic manner.

We are a clinical-stage company pioneering TPD, a powerful new modality, with the aim of delivering breakthrough treatments for people around the world. TPD engages the body's natural cellular recycling system to selectively eliminate disease-causing proteins, ultimately addressing the root cause of disease. This technology enables us to address promising disease targets that are beyond the reach of conventional medicines.

Vision

Reinvent the treatment of human disease

Mission

Build a global medicines company that harnesses novel modalities to revolutionize healthcare

LINKEDIN Kymera Therapeutics

TWITTER/X @KymeraTx

сомтаст media@kymeratx.com


200 Arsenal Yards Blvd., Suite 230, Watertown, MA 02472 © 2024 Kymera Therapeutics. All Rights Reserved.

, KYMERA

We're building a fully integrated biopharmaceutical company that will meaningfully impact areas of significant patient need through our unique nexus of biology, proprietary chemistry, data science, and translational research approaches. Our programs address well-validated disease targets and broader biological pathways in therapeutic areas affecting large numbers of patients, where TPD is the best or only option to transform the standard of care.

We have advanced the first oral small molecule degrader into the clinic for immunological diseases, and we're expanding our focus in immunology to deliver small molecule oral degrader drugs to help patients without treatment options, or to provide convenient, highly effective therapies in place of injectable biologics. We are also progressing degrader programs in oncology that target undrugged or poorly drugged proteins to create new ways to fight cancer that can potentially treat both solid and liquid tumors.

We push boundaries with an incredible sense of urgency, knowing patients are waiting for our therapies, and that every week, every day, every hour counts. Our unique target selection strategy and data-driven approach have catalyzed the development of our current pipeline of clinical stage oncology and immunology programs, and a disease-agnostic discovery engine that enables us to deliver at least one new molecular entity into the clinic per year.





- We've consistently replicated fidelity of translation of PK/PD and safety from preclinical models to patients with our programs, validating our molecular design and clinical strategy.
- Through this work, we have expanded the potential of this field, demonstrating that degraders can be used safely and effectively outside of oncology in complex diseases like HS and AD.

Propelling our rigorous scientific approach is a relentless desire to improve – to expand the opportunity and application of our science, scale our capabilities to support a rapidly maturing company, and build a culture that enables us to achieve what may have seemed impossible. Our shared values and a deep commitment to improving patients' lives are the guiding principles that drive our work and connect our diverse and experienced teams to the mission of Kymera.



200 Arsenal Yards Blvd., Suite 230, Watertown, MA 02472 © 2024 Kymera Therapeutics. All Rights Reserved.